Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
8
PET/CT scan with F18-PSMA-11
University hospital Ghent
Ghent, Belgium
Demonstrate uptake of 18F-PSMA-11 in RAI-RTC
Confirmation in PET-scan that lesions in RAI-RTC show uptake of 18F-PSMA-11, above background activity in the bloodpool.
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Perform a semi-quantitative analysis of radiotracer uptake in lesions.
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Perform a lesion detection rate analysis on organ level.
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Compare uptake of 18F-PSMA-11 in these patients to the uptake of 18F-FDG, on a lesion basis.
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Evaluate the sufficiency of uptake of 18F-PSMA-11 to consider therapy with 177Lu-PSMA in a subset of patients
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Compare the histological expression of PSMA on already available tumor samples with the uptake of lesions on PSMA PET.
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Analyse the correlation between the serum level of PSMA and the uptake on PSMA PET
Time frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
Compare the histological expression of PSMA on already available tumor samples with the serum level of PSMA.
Time frame: Within 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.